Nalaganje...
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
BACKGROUND: MLN0128 is a first-in-class, dual mTOR inhibitor with potential to outperform standard rapalogs through inhibition of TORC1 and TORC2. This phase II study was designed to assess antitumor activity of MLN0128 in metastatic castration-resistant prostate cancer (mCRPC). METHODS: Eligible pa...
Shranjeno v:
| izdano v: | Invest New Drugs |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6050986/ https://ncbi.nlm.nih.gov/pubmed/29508246 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0578-9 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|